Saturday 17 October 2026
Export GTBP’s income statement to Excel — free account
GT Biopharma, Inc.
GTBP Healthcare Biotechnology
In the quarter to June 2026, EPS grew 98.9% and free cash flow fell 41.3%, each against the same quarter a year earlier.
7.03
0.33
−4.48%
Follow GTBP
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Current Ratio |
0.00 | 0.22 | 0.01 | 0.01 | 0.16 | 3.14 | 3.35 | 2.12 | 0.72 | 3.50 |
Net Debt/EBITDA |
(1.73) | 0.00 | (0.04) | (0.85) | (3.26) | 0.56 | 0.78 | 1.03 | 0.28 | 0.56 |
Debt/Assets |
44,956.00% | 0.01% | 42.02% | 3,335.10% | 464.64% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
(0.59) | 0.00 | 0.94 | (0.68) | (0.89) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
(0.20) | 0.04 | 0.04 | 0.09 | 0.26 | 0.27 | 0.73 | 1.17 | 0.98 | 0.37 |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.39 | 0.00 | — | — | — | — | — |
Interest Coverage |
(1.43) | (15.76) | (27.43) | (7.55) | (2.25) | (80.10) | (2,657.12) | (63.74) | — | (97.81) |
| (28.11%) | (123.88%) | (197.06%) | 972.88% | 116.09% | 1,541.48% | (124.15%) | (79.10%) | (453.55%) | (1,674.31%) | |
| 24,729.11% | (113.35%) | (185.29%) | (299.65%) | (934.32%) | (306.70%) | (85.41%) | (49.26%) | (143.53%) | (558.42%) | |
ROIC |
0.00% | (33.74%) | (710.97%) | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(51.62%) | 6,875.15% | 1,864.11% | 198.88% | 96.14% | (264.78%) | (179.66%) | (102.34%) | 788.14% | (595.28%) |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 1.00 | 0.99 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Free Cash Flow per Share |
0.00 | (4,180.00) | (2,746.92) | (768.67) | (1,252.07) | (416.16) | (358.05) | (164.23) | (170.01) | (58.57) |
Cash per Share |
0.00 | 443.08 | 15.38 | 6.22 | 913.28 | 852.77 | 388.42 | 259.22 | 53.28 | 31.32 |
Shareholders Equity per Share |
0.00 | 193,606.92 | 2,915.38 | (4,291.11) | (5,074.66) | 584.27 | 276.09 | 138.70 | (22.00) | 26.24 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
0.00 | 193,606.92 | 2,915.38 | (4,291.11) | (5,074.66) | 584.27 | 276.09 | 138.70 | (22.00) | 26.24 |
Free Cash Flow |
(1.93) | (5.43) | (10.71) | (3.46) | (7.26) | (15.61) | (15.22) | (8.85) | (12.90) | (12.91) |
Working Capital |
(18.93) | (2.10) | (13.94) | (19.43) | (29.43) | 21.91 | 11.62 | 7.42 | (1.67) | 5.79 |
Capital Expenditures |
— | 0.00 | (0.04) | 0.20 | — | — | — | — | — | — |
Net Current Asset Value |
(18.93) | (2.10) | (13.94) | (19.43) | (29.43) | 21.91 | 11.56 | 7.42 | (1.67) | 5.79 |
| Other line items | ||||||||||
Quick Ratio |
0.00 | 0.22 | 0.00 | 0.00 | 0.15 | 3.12 | 3.34 | 2.11 | 0.69 | 2.98 |
Depreciation/Fixed assets |
724.50 | 819.33 | 278.46 | 0.00 | 0.00 | — | 0.00 | — | — | — |
Cash ROIC |
25.18% | (2.15%) | (48.47%) | 56.94% | (335.12%) | (28.96%) | (53.88%) | (41.27%) | (543.56%) | (101.75%) |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — | — |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
0.00 | (4,176.92) | (2,737.69) | (813.11) | (1,252.07) | (416.16) | (358.05) | (164.23) | (170.01) | (58.57) |
Capex per Share |
0.00 | (3.08) | (9.23) | 44.44 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Payables |
1.50 | 2.32 | 2.15 | 1.85 | 2.09 | 5.22 | 5.66 | 3.73 | 4.09 | 2.30 |
Average Assets |
0.04 | 127.20 | 139.88 | 12.90 | 3.03 | 18.92 | 24.45 | 15.42 | 9.17 | 6.17 |
Average Common Equity |
(34.75) | 116.38 | 131.53 | (3.97) | (24.37) | (3.76) | 16.82 | 9.60 | 2.90 | 2.06 |
Capex to Sales |
— | 0.00 | 0.00 | 0.00 | — | — | — | — | — | — |
Columns are period end dates